{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:03Z","timestamp":1792790463947,"version":"4.5.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Tisagenlecleucel (tisa-cel) is a CD19-directed chimeric antigen receptor T-cell therapy for relapsed\/refractory precursor B-cell acute lymphoblastic leukemia (R\/R B-ALL). We report infectious complications for 100 days (D100) following tisa-cel therapy in 471 pediatric and young adults (median age 13.8 years) with R\/R B-ALL reported from September 2017 to June 2022. By D100, 137 (29%) patients had an infectious event, with an infection density of 0.542 per 100 person-days at risk. D100 cumulative incidences of bacterial, viral, and fungal infections were 14.1%, 11.6%, and 1.3%, corresponding to infection density scores of 0.296, 0.213, and 0.033 per 100 person-days at risk, respectively. In a multivariable analysis, receipt of \u22653 lines of therapy before tisa-cel (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.13-3.08; P = .015), any-grade cytokine release syndrome (HR, 1.78; 95% CI, 1.17-2.71; P = .007), and lack of neutrophil recovery (HR, 2.63; 95% CI, 1.47-4.69; P = .001) were associated with an increased risk for any infection. Similar associations were observed for bacterial infections, with the addition of younger age as an adverse risk (&amp;lt;6 vs 6-15 years; HR, 2.38; 95% CI, 1.23-4.61; P = .01). Risk factors for viral infections included increasing age (1-year increase; HR, 1.05; 95% CI, 1.01-1.09; P = .016), prior history of any infection (HR, 2.76, 95% CI, 1.40-5.46; P = .004), and prior hematopoietic cell transplant (HR, 2.10; 95% CI, 1.18-3.71; P = .011). D100 infection-related mortality (IRM) rate was low at 0.2% (95% CI, 0.0-0.8). In this multicenter real-world study, we observed a high incidence of infectious complications but a low IRM following tisa-cel for R\/R B-ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016149","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:00:56Z","timestamp":1753902056000},"page":"5489-5500","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-2920","authenticated-orcid":false,"given":"Hemalatha G.","family":"Rangarajan","sequence":"first","affiliation":[{"name":"1Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Satwani","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-681X","authenticated-orcid":false,"given":"Michael J.","family":"Martens","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"},{"name":"5Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitsada","family":"Wudhikarn","sequence":"additional","affiliation":[{"name":"6Center of Excellence in Translational Hematology and Division of Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"John","sequence":"additional","affiliation":[{"name":"7Division of Pediatric Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa A.","family":"Fabrizio","sequence":"additional","affiliation":[{"name":"8Department of Pediatric Hematology, Oncology, and Bone Marrow Transplant, University of Colorado Anschutz, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Hsieh","sequence":"additional","affiliation":[{"name":"9Division of Hematology\/Oncology\/Transplantation & Cellular Therapy, Children\u2019s Hospital Los Angeles, Keck School of Medicine of University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-8509","authenticated-orcid":false,"given":"Amar H.","family":"Kelkar","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Doherty","sequence":"additional","affiliation":[{"name":"11Department of Pediatrics, Center for Cell and Gene Therapy, Texas Children\u2019s Hospital\/Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Marks","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Bristol Hematology and Oncology Unit, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6092-1536","authenticated-orcid":false,"given":"Olle","family":"Ringden","sequence":"additional","affiliation":[{"name":"13Department of Clinical Science, Intervention and Technology, Translational Cell Therapy Group, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8652-4400","authenticated-orcid":false,"given":"Brian","family":"Friend","sequence":"additional","affiliation":[{"name":"14Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8819-2315","authenticated-orcid":false,"given":"Matthew S.","family":"Kelly","sequence":"additional","affiliation":[{"name":"15Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nosha","family":"Farhadfar","sequence":"additional","affiliation":[{"name":"16Division of Hematology, Sarah Cannon Transplant & Cellular Program at Methodist Hospital, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4078-5001","authenticated-orcid":false,"given":"Tim","family":"Prestidge","sequence":"additional","affiliation":[{"name":"17Department of Blood and Cancer, Blood and Cancer Centre, Starship Children\u2019s Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-655X","authenticated-orcid":false,"given":"Nasheed M.","family":"Hossain","sequence":"additional","affiliation":[{"name":"18Division of Hematology\/Oncology - Cell Therapy and Transplantation Program, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-7807","authenticated-orcid":false,"given":"Hongtao","family":"Liu","sequence":"additional","affiliation":[{"name":"19Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7927","authenticated-orcid":false,"given":"Shahrukh","family":"Hashmi","sequence":"additional","affiliation":[{"name":"20Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates"},{"name":"21Department of Medicine, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-8844","authenticated-orcid":false,"given":"Dipenkumar","family":"Modi","sequence":"additional","affiliation":[{"name":"22Division of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-1594","authenticated-orcid":false,"given":"Lena E.","family":"Winestone","sequence":"additional","affiliation":[{"name":"23Division of Allergy, Immunology, and Blood & Marrow Transplant, University of California San Francisco Benioff Children\u2019s Hospitals, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"El Boghdadly","sequence":"additional","affiliation":[{"name":"24Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-4248","authenticated-orcid":false,"given":"Hemant S.","family":"Murthy","sequence":"additional","affiliation":[{"name":"25Division of Hematology\/Oncology, Mayo Clinic Florida, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"26Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"27Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-3088","authenticated-orcid":false,"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[{"name":"14Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4001-9203","authenticated-orcid":false,"given":"Christopher E.","family":"Dandoy","sequence":"additional","affiliation":[{"name":"28Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Disease Institute, Cincinnati Children\u2019s Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-9834","authenticated-orcid":false,"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[{"name":"29Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"30Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1263-6623","authenticated-orcid":false,"given":"Anna","family":"Huppler","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"},{"name":"31Division of Pediatric Infectious Diseases, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcie","family":"Riches","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1515-2141","authenticated-orcid":false,"given":"Jeffery J.","family":"Auletta","sequence":"additional","affiliation":[{"name":"32Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, MN"},{"name":"33Hematology, Oncology & Blood and Marrow Transplant and Infectious Diseases, Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"10","key":"2025111015015893000_bib1","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/s41591-019-0596-y","article-title":"Developing neoantigen-targeted T cell-based treatments for solid tumors","volume":"25","author":"Yamamoto","year":"2019","journal-title":"Nat Med"},{"issue":"10416","key":"2025111015015893000_bib2","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"2025111015015893000_bib3","first-page":"594","article-title":"Updated indications for immune effector cell therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy","volume":"29","author":"Kanate","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"26","key":"2025111015015893000_bib4","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2025111015015893000_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"2025111015015893000_bib6","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2025111015015893000_bib7","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2025111015015893000_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2021-146393","article-title":"Real-world outcomes for pediatric and young adult patients with relapsed or refractory (R\/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry","volume":"138","author":"John","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2025111015015893000_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2025111015015893000_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2025111015015893000_bib11","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"2025111015015893000_bib12","doi-asserted-by":"crossref","first-page":"e14202","DOI":"10.1111\/tid.14202","article-title":"Infections in children following chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia","volume":"25","author":"Diamond","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2025111015015893000_bib13","doi-asserted-by":"crossref","first-page":"845540","DOI":"10.3389\/fonc.2022.845540","article-title":"Infectious complications in pediatric, adolescent and young adult patients undergoing CD19-CAR T cell therapy","volume":"12","author":"Maron","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"2025111015015893000_bib14","doi-asserted-by":"crossref","first-page":"e002287","DOI":"10.1136\/jitc-2020-002287","article-title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","volume":"9","author":"Levine","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025111015015893000_bib15","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"issue":"1","key":"2025111015015893000_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2017-11-812982","article-title":"CD19 CAR-T therapy and sepsis: dancing with the devil","volume":"131","author":"Budde","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2025111015015893000_bib17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cmi.2023.05.011","article-title":"Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: a systematic scoping review and narrative synthesis","volume":"29","author":"Reynolds","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2025111015015893000_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/hematology.2024000535","article-title":"Mitigating and managing infection risk in adults treated with CAR T-cell therapy","volume":"2024","author":"Tabbara","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"10","key":"2025111015015893000_bib19","first-page":"955","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"2025111015015893000_bib20","unstructured":"Center for International Blood and Marrow Transplant Research\n          . Stem cell therapeutic and research act of 2005 (SCTOD) requirements. Accessed 5 August 2025. https:\/\/cibmtr.org\/CIBMTR\/Data-Operations\/Center-Membership\/SCTOD-Requirements."},{"key":"2025111015015893000_bib21","unstructured":"Center for International Blood and Marrow Transplant Research\n          . Lines of therapy: acute lymphoblastic leukemia (ALL) - forms instruction manual - 1. Accessed 5 August 2025. https:\/\/www.manula.com\/manuals\/cibmtr\/fim\/1\/en\/topic\/all-lines-of-therapy."},{"issue":"8","key":"2025111015015893000_bib22","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"2025111015015893000_bib23","unstructured":"Center for International Blood and Marrow Transplant Research\n          . Forms manual appendix J: reporting comorbidities. Accessed 5 August 2025. https:\/\/cibmtr.org\/Files\/Data-Operations\/Retired-Forms-Manuals\/Appendix-J_V3_Retired.pdf."},{"issue":"1","key":"2025111015015893000_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2025111015015893000_bib25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"2025111015015893000_bib26","unstructured":"Center for International Blood and Marrow Transplant Research\n          . CIBMTR forms instruction manual. Accessed 5 August 2025. https:\/\/www.manula.com\/manuals\/cibmtr\/fim\/1\/en\/topic\/4100q79-174."},{"issue":"1","key":"2025111015015893000_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025111015015893000_bib28","unstructured":"Center for International Blood and Marrow Transplant Research\n          . Forms manual: Q178-189: infection. Accessed 5 August 2025. https:\/\/www.manula.com\/manuals\/cibmtr\/fim\/1\/en\/topic\/4100q175-179."},{"issue":"1","key":"2025111015015893000_bib29","first-page":"114.e1","article-title":"Incidence and impact of fungal infections in post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research analysis","volume":"30","author":"Papanicolaou","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2025111015015893000_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00985764","article-title":"Score test of homogeneity for survival data","volume":"1","author":"Commenges","year":"1995","journal-title":"Lifetime Data Anal"},{"issue":"408","key":"2025111015015893000_bib31","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions","volume":"84","author":"Wei","year":"1989","journal-title":"J Am Stat Assoc"},{"issue":"23","key":"2025111015015893000_bib32","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2025111015015893000_bib33","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"suppl 1","key":"2025111015015893000_bib34","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"2025111015015893000_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-024-01038-2","article-title":"Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r\/r ALL through a national access scheme","volume":"14","author":"Oporto Espuelas","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025111015015893000_bib36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ejh.13712","article-title":"Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells","volume":"108","author":"Beyar-Katz","year":"2022","journal-title":"Eur J Haematol"},{"issue":"14","key":"2025111015015893000_bib37","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","article-title":"Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy","volume":"8","author":"Lin","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"2025111015015893000_bib38","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"issue":"20","key":"2025111015015893000_bib39","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025111015015893000_bib40","first-page":"430","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2025111015015893000_bib41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2025111015015893000_bib42","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5489\/2418572\/blooda_adv-2025-016149-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5489\/2418572\/blooda_adv-2025-016149-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T20:02:08Z","timestamp":1762804928000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/21\/5489\/546409\/Real-world-outcomes-of-infections-following"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":42,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016149","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,11]]},"published":{"date-parts":[[2025,10,30]]}}}